Drugs and the FDA
Safety, Efficacy, and the Public's Trust
$46.26
- Paperback
320 pages
- Release Date
12 March 2024
Summary
Drugs and the FDA
The Food and Drug Administration’s approval of COVID-19 vaccines and the controversial Alzheimer’s drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate US authority on a drug’s safety and efficacy? In Drugs and the FDA, Mikkael Sekeres—a leading oncologist and former chair of the FDA’s cancer drug advisory committee—tells the story of how the FDA became the most trusted regulatory agency in th…
Book Details
| ISBN-13: | 9780262548397 |
|---|---|
| ISBN-10: | 0262548399 |
| Author: | Mikkael A. Sekeres |
| Publisher: | MIT Press Ltd |
| Imprint: | MIT Press |
| Format: | Paperback |
| Number of Pages: | 320 |
| Release Date: | 12 March 2024 |
| Weight: | 369g |
| Dimensions: | 229mm x 152mm |
You Can Find This Book In
What They're Saying
Critics Review
“It’s a physician’s-eye-view on the products that fill our medicine cabinets, but Sekeres includes patients in the mix, too. A public that, in his words, ‘revolts, protesting loudly enough to be heard, to provoke change’ is the true driver of this engaging book.”
—Erin Blakemore, The Washington Post
“A thought-provoking book that confronts readers with all of these difficult questions while keeping them glued to their seats through Sekeres’s skillful and self-reflective retelling of the Avastin hearings.”
—Bill of Health, Harvard Law School
About The Author
Mikkael A. Sekeres
Mikkael A. Sekeres is Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, and former Chair of the Oncologic Drugs Advisory Committee of the FDA. A regular contributor to the Well section of the New York Times, he is the author of When Blood Breaks Down- Life Lessons from Leukemia (MIT Press).
Returns
This item is eligible for free returns within 30 days of delivery. See our returns policy for further details.